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Horizontal transmission of rotavirus vaccine virus may contrib-
ute to indirect effects of rotavirus vaccine, but data are lacking 
from low-income countries. Serial stool samples were obtained 
from Malawian infants who received 2 doses of monovalent 
human rotavirus vaccine (RV1) (days 4, 6, 8, and 10 after vac-
cination) and from their household contacts (8–10  days after 
vaccine). RV1 vaccine virus in stool was detected using semi-
quantitative real-time  reverse-transcription polymerase chain 
reaction. RV1 fecal shedding was detected in 41 of 60 vacci-
nated infants (68%) and in 2 of 147 household contacts (1.4%). 
Horizontal transmission of vaccine virus within households is 
unlikely to make a major contribution to RV1 indirect effects 
in Malawi.
Keywords. rotavirus; vaccine; indirect effects; transmis-
sion; Malawi.
Programmatic introduction of rotavirus vaccines has led to 
substantial reductions in the global burden of severe rotavi-
rus gastroenteritis; however, rotavirus vaccine effectiveness is 
significantly lower in low-income than in higher-income set-
tings [1]. Rotavirus remains a major cause of severe gastro-
enteritis in African children, with an estimated 121 009 deaths 
from rotavirus gastroenteritis in sub-Saharan Africa in 2013 
[2]. In this context, indirect effects of rotavirus vaccine, which 
have been well documented in high-income settings [3], could 
make an important contribution to overall vaccine impact. 
Mechanisms of indirect effects of rotavirus vaccine may include 
reduction in transmission of wild-type rotavirus and/or hori-
zontal transmission of vaccine virus to contacts after excretion 
in stool of vaccinated infants.
Live oral rotavirus vaccines mimic natural infection, repli-
cating in the gastrointestinal tract before being shed in stool. 
Several studies have demonstrated horizontal transmission of 
rotavirus vaccine virus from vaccinated infants to close con-
tacts; reported transmission rates range from 0% to 18.8% [4–
6]. The protective effects of horizontal transmission of vaccine 
virus to unvaccinated individuals has been well described for 
oral polio vaccine [7], but the role of such transmission in gen-
erating vaccine indirect effects for rotavirus is not established.
To our knowledge  transmission of rotavirus vaccine virus has 
not previously been investigated in Africa, where—compared 
with higher-income countries—differences in host vaccine 
response, population structure, contact patterns, sanitation, 
and underlying comorbid conditions [1] could affect both vac-
cine virus shedding in vaccine recipients and susceptibility of 
close contacts to infection. We undertook a prospective cohort 
study in Malawi, a low-income African country with a high 
burden of rotavirus disease. The monovalent human rotavirus 
vaccine (RV1; Rotarix) was introduced in Malawi in 2012, with 
doses delivered at 6 and 10 weeks of age. Postimplementation 
effectiveness has been reported at approximately 60% [8]. We 
aimed to estimate the proportion of household contacts of RV1-
vaccinated infants who subsequently shed vaccine-type virus.
METHODS
Study Design and Procedures
We conducted a prospective cohort study between April and 
August 2016. After informed consent, consecutive infants 
attending a government health center for routine vaccinations 
were recruited (index infants) together with their household 
contacts (children and adults).
Index infants had a prevaccine baseline stool sample col-
lected at recruitment and 4, 6, 8, and 10 days after vaccination. 
Stool samples were collected from household contacts before 
administration of the first vaccine dose to the index infant and 
8–10 days after administration of each vaccine dose. Sampling 
times were based on local pilot data and prior studies of infant 
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vaccine virus shedding and assumed peak shedding at day 
6, with 2–3  days allowed for transmission to and subsequent 
shedding in contacts [4, 5]. Maternal human immunodeficiency 
virus (HIV) status was extracted from hand-held government 
health records, or by maternal report when records were 
unavailable. HIV exposure was defined as an infant born to an 
HIV-infected mother.
Stool specimens were tested for rotavirus using VP6 
semi-quantitative real-time reverse transcription polymerase 
chain reaction (qRT-PCR) [9] and vaccine virus–specific NSP2 
qRT-PCR [10]. Assays were considered positive if the cycle 
threshold (Ct) value was <40. Samples positive by both NSP2 
qRT-PCR and VP6 qRT-PCR were classified as positive for vac-
cine virus. Samples positive by VP6 qRT-PCR but negative by 
NSP2 qRT-PCR were assumed to represent wild-type rotavirus. 
In index infants, postimmunization vaccine virus shedding was 
defined as ≥1 confirmed postvaccination virus-positive sample.
We used χ2 tests to compare categorical variables and 
McNemar tests to compare paired proportions before and after 
exposure. The study was powered to detect a difference in the 
paired proportion of individuals shedding vaccine virus before 
and after exposure to a vaccinated infant, with 80% power and 
an α value of .05 determined with the McNemar test [11] and 
assuming a shedding frequency of 50% in recently vaccinated 
infants (based on pilot data in the same population). A  sam-
ple of 60 infants (and their household contacts) was required 
in order to detect a postexposure increase in shedding of 
≥30%; we planned to recruit 75 infants to allow for loss to fol-
low-up. This study was approved by the University of Liverpool 
Research Ethics committee (Application numbers 000757 and 
000758) and the Malawi College of Medicine Research Ethics 
Committee (Application numbers P.09/14/1623 and 1624).
RESULTS
A total of 72 households were recruited. Of these, 69 house-
holds (69 index infants, 147 household contacts) completed 
follow-up. The median age of infants at recruitment was 6.1 
weeks (range, 5.1 to 8.7 weeks). Of the 69 infants, all were 
exclusively breastfed, 29 (42%) were male, and 12 (17%) were 
HIV exposed. Of the HIV-exposed infants, 5 were HIV unin-
fected (PCR negative for HIV DNA) at 6 weeks of age; the 
HIV status of the other 7 exposed infants was unknown at 
the end of follow-up.
Owing to infrequent passing of stool in breastfed infants and 
logistic constraints, stool samples were not available for every 
vaccine-recipient infant at every collection time point. Among 
infants with a baseline stool sample, 1 of 33 samples (3%; 95% 
confidence interval [CI], 0.4%–20%) was weakly positive for 
vaccine virus (Ct value 38.6). Wild-type rotavirus was detect-
able at baseline in 5 of 33 samples (15%; 95% CI, 6%–33%), 
with a median Ct value of 38.5 (interquartile range [IQR], 
37.9–38.6). Of 60 index infants who provided sufficient stool 
for analysis of both dose periods, 41 (68%; 95% CI, 55%–79%) 
had detectable vaccine virus shedding after either dose 1 or 
dose 2. Shedding was detected early, with first detection by day 
6 in 25 of 29 infants (86%) who shed in the first dose period 
and 26 of 34 (76%) who shed in the second dose period (Table 
1). Shedding density was low, with a peak shedding median Ct 
value of 32.2 (IQR, 29.9–35.8) after the first vaccine dose and 
32.8 (30.5–35.5) after dose 2.  The RV1 shedding patterns by 
dose period are provided in Supplementary Table 1.
Of 147 household contacts recruited (46 of 147 [31%] male; 
median age, 21 years; range, 0–41 years), 119 provided prevac-
cine stool samples, 138 provided samples after the first dose, 122 
after dose 2, and 113 after both doses. Postvaccination samples 
were collected a median of 8 days (IQR, 8-8 days) after dose 1 
and 8 days (8–11 days) after dose 2. Characteristics of house-
hold contacts are shown in Table 2. There were no reported 
episodes of gastroenteritis in household contacts during the 
follow-up period. No contacts shed vaccine virus before expo-
sure to a vaccinated infant. A total of 2 of 113 (1.8%; 95% CI, 
0.4%–6.9%) household contacts, from different households, 
shed vaccine virus after exposure to a vaccinated infant; these 
contacts included 1 sibling (aged 3 years, HIV status unknown) 
and 1 mother (aged 34 years, HIV negative).
Wild-type rotavirus was detectable in at least 1 stool sam-
ple in 35 of 147 household members (24%; 95% CI, 18%–31%). 
Shedding was low level (median Ct value, 39; IQR, 36–39). There 
was no difference in the frequency of wild-type shedding with 
age: 6 of 20 children <5 years old (30%) shed wild-type virus, 
compared with 29 of 127 (23%) >5 years old (P = .484). Viral 
loads in wild-type infections were too low to allow genotyping.
DISCUSSION
To our knowledge this is the first study to investigate rotavirus 
vaccine virus transmission in households in a low-income 
Table 1. Proportion of Infants With RV1 Vaccine Virus Shedding After RV1 Immunization
Dose Period Infants With RV1 Vaccine Virus Shedding, No./Total (%; 95% CI)
 Day 4 Day 6 Day 8 Day 10 Overall
First 15/58 (26; 16–39) 18/61 (30; 19–42) 15/56 (27; 17–40) 12/65 (18; 20–30) 29/68 (43; 31–55)
Second 20/57 (35; 24–48) 21/60 (35; 24–48) 20/57 (35; 24–49) 17/55 (31; 20–45) 34/64 (53; 41–65)
Abbreviations: CI, confidence interval; RV1, monovalent human rotavirus vaccine.
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setting. We found a very low rate of horizontal transmission of 
rotavirus vaccine virus to household contacts, despite a high 
frequency of vaccine virus shedding among vaccinated infants. 
The low transmission rates of vaccine virus observed in our 
study are consistent with a study in a foster home in Japan, 
which reported no horizontal transmission (determined by 
means of RT-PCR in serial samples) among 22 unvaccinated 
infant contacts of 4 vaccinated infants [5]. Horizontal trans-
mission rates to placebo recipients were also low (0%–3%) in 
several prelicensure vaccine trials from high- and middle-in-
come countries [6], although transmission to community con-
tacts might be expected to be lower than transmission within 
households.
Reported rates of horizontal transmission were much higher 
in a clinical trial in the Dominican Republic, in which twins 
were randomized to receive either RV1 or placebo [4]. Vaccine 
virus fecal shedding was detected in 15 of 80 placebo recipients 
(18.8%), although 5 of 15 transmission events (33%) preceded 
or coincided with detectable shedding in the vaccine recipient 
and may have been false-positives. A higher transmission rate 
between twins might also be expected because of lower pre-
existing immunity to rotavirus (owing to very young age) and 
very close contact with the vaccinated infant. In a mother-infant 
study from South Africa, mothers of vaccinated infants were 
noted to have higher antirotavirus immunoglobulin A  titers 
after vaccination of their infants [12]. The authors suggested 
that this could imply horizontal transmission, but infant fecal 
shedding was not measured and a rise secondary to maternal 
wild-type infection could not be excluded. However, it is possi-
ble that in countries with higher vaccine efficacy than Malawi, 
such as South Africa, vaccine virus shedding in infants may be 
higher and horizontal transmission effects could occur.
Our study has several strengths. First, prior studies have 
reported vaccine virus transmission only to other infants, 
which in the context of universal rotavirus immunization is 
perhaps less relevant to indirect vaccine effects than transmis-
sion to older children and adults. Second, our study used qRT-
PCR to detect vaccine virus shedding. The majority of previous 
studies have used enzyme immunosassay or cell culture, both of 
which are considerably less sensitive than qRT-PCR. Finally, to 
our knowledge, this is the only study of rotavirus vaccine virus 
transmission conducted in a setting with high background HIV 
prevalence. Malawi has an HIV prevalence of 13% in women 
of childbearing age; HIV has been associated with prolonged 
rotavirus shedding [13], and HIV-infected household contacts 
could be more susceptible to vaccine virus infection. The very 
low frequency of vaccine virus transmission observed in the 
current study argues against any increased risk of transmission 
associated with household HIV exposure; however, data from a 
larger cohort are required.
A limitation of our study is the relatively sparse sampling 
of household contacts owing to logistical constraints, making 
it possible that transient very early or late shedding episodes 
were not detected. However, shedding of vaccine virus occurred 
early in vaccinated infants; vaccine virus was detected by day 
6 after vaccination in about 80% of infants with fecal shed-
ding. Furthermore, the molecular detection methods used are 
highly sensitive even for very low-level viral shedding. In the 
Dominican study, most transmission events occurred within 
the first 10 days after immunization [4], and our study findings 
are also corroborated by those from the study in Japan, which 
sampled at multiple time points [5]. An additional limitation of 
our study population is that there were relatively few young chil-
dren or infants among our household contacts. Older children 
and adults are more likely to be partially immune to rotavirus, 
Table 2. Characteristics of Households and Household Contacts
Characteristic 
Households or Contacts,  
No. (%; 95% CI %) 
Households (n = 69)
 Other children aged <5 y in household 23 (33; 23–46)
 Toilet shared with other households 54 (78; 67–87)
 Typical time required to access water, mins  
  <5 30 (44; 32–56)
  5–30 36 (52; 40–64)
  >30 3 (4; 1–13)
 Typical source of domestic water  
  Well 1 (1.5; 0.2–10)
  Borehole 4 (6; 2–15)
  Tap shared with other households 50 (72; 60–82)
  Private tap to house 14 (20; 12–32)
Household contacts (n=147)  
 Age, y  
  <5 20 (14; 9–20)
  5–15 30 (20; 15–28)
  15–45 97 (66; 58–73)
 Male sex 46 (31; 24–39)
 HIV infected 13/77 (17; 10–27)
 Relationship to infant  
  Mother 69 (47; 39–55)
  Father 20 (14; 9–20)
  Other adult relative 4 (3; 1–7)
  Child relative 54 (37; 29–45)
 Prior rotavirus vaccine in contacts aged <5 y 8/17 (44; 24–72)
 Sleeps in same room as vaccinated infant 108 (73; 66–80)
 Sleeps in same bed as vaccinated infant 91 (62; 54–69)
 Time spent with child  
  All day 83 (56; 48–64)
  Half day 42 (29; 22–36)
  Evening only 22 (15; 10–22)
 Primary caregiver for vaccinated infant 71 (48; 40–56)
 Responsible for changing diaper of vacci-
nated infant
 
  Never 75 (51; 43–59)
  Sometimes 3 (2; 1–6)
  Always 69 (47; 39–55)
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus.
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which may contribute to the observed low frequency of hori-
zontal transmission. Our findings may represent a minimum 
estimate of horizontal transmission, but given the very small 
number of transmission episodes identified, it seems unlikely 
that the true frequency should be substantially higher.
In contrast to the low frequency of vaccine virus shedding 
among household members, wild-type rotavirus shedding in 
household members was common (24%), consistent with previ-
ous local data [14]. Wild-type rotavirus shedding in household 
members is most likely a result of transmission from a symp-
tomatic child. Although no symptomatic cases were recorded at 
the time of sampling, shedding in case patients and their con-
tacts can be prolonged after an episode of rotavirus diarrhea. 
Possible explanations for the difference in transmission rates 
of wild-type versus vaccine virus could include differences in 
viral load and symptoms in symptomatic children compared 
with vaccine recipients. Viral load is much higher in symptom-
atic children: in a previous Malawian study [14], children with 
rotavirus gastroenteritis had a median Ct value of 19 compared 
with a median of 32 for vaccine virus shedding in this study. 
The importance of symptoms in transmission is demonstrated 
by a study from Ecuador, which identified rotavirus infection in 
55% of household contacts of symptomatic index case patients, 
compared with 2% of household contacts of healthy control 
children, and found an association between symptom severity 
and risk of transmission [15].
In conclusion, this study identified very little horizontal 
transmission of vaccine virus to household contacts in urban 
Malawi, despite high background HIV prevalence, crowded liv-
ing conditions, and poor sanitation. Horizontal transmission of 
vaccine virus seems unlikely to be a major contributing factor 
to indirect vaccine effects in this setting.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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